Table 4.
Odds ratios (95 % CI) for the ten thrombophilic mutations in case and control groups
| Mutation | Case (n = 89) | Control (n = 50) | P -value | OR | 95 % confidence interval of an odds ratio | ||
|---|---|---|---|---|---|---|---|
| Carriera (%) | Non-carrierb (%) | Carriera (%) | Non-carrierb (%) | ||||
| FV 1691G/A | 2.25 | 97.75 | 0 | 100 | 0.536 | 1.023 | 0.991–1.056 |
| FV HR2 4070 A/G | 4.49 | 95.51 | 4 | 96 | 1.000 | 1.129 | 0.199–6.395 |
| F II 20210 G/A | 2.25 | 97.75 | 0 | 100 | 0.536 | 1.023 | 0.991–1.056 |
| PAI-1 (-675 I/D, 5G/4G) | 70.79 | 29.21 | 70 | 30 | 1.000 | 1.030 | 0.487–2.216 |
| ACE (intron 16 I/D) | 74.16 | 25.84 | 86 | 14 | 0.133 | 0.467 | 0.184–1.183 |
| Factor VII (Gln353Arg) | 37.08 | 62.92 | 46 | 54 | 0.363 | 0.692 | 0.342–1.397 |
| Factor XIII (Val34Leu) | 33.71 | 66.29 | 24 | 76 | 0.254 | 1.610 | 0.735–3.526 |
| BF (-455G/A) | 49.46 | 50.56 | 52 | 48 | 0.860 | 0.903 | 0.451–1.805 |
| G Ia (807C/T) | 68.54 | 31.46 | 64 | 36 | 0.707 | 1.225 | 0.590–2.544 |
| tPA (intron 8 D/I) | 57.31 | 42.69 | 58 | 42 | 1.000 | 0.972 | 0.482–1.960 |
FV Factor V; FV HR2 Factor V-His1299 Arg; F II Factor II or Prothrombin; PAI-1 Plasminogen Activator Inhibitor-1; ACE Angiotansine Converting Enzume; F VII Factor VII; F XIII Factor XIII; BF beta fibrinogen; G Ia Glycoprotein Ia; tPA tissue Plasminogen Activator
aCarriers: individuals who had either heterozygous or homozygous specified mutation
bNon-carriers: individuals who had neither heterozygous nor homozygous specified mutation